MIRA PHARMACEUTICALS, INC.
About MIRA PHARMACEUTICALS, INC.
Mira Pharmaceuticals Inc is a clinical-stage pharmaceutical development company focused on developing novel oral small-molecule therapeutics for neurologic, neuropsychiatric, metabolic, and inflammatory disorders. The company's pipeline includes three product candidates: Ketamir-2, MIRA-55, and SKNY-1, three drug candidates designed to address unmet medical needs across neuropathic and inflammatory pain, central nervous system disorders, and metabolic and behavioral conditions. The company operates as a single operating and reportable segment.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$10.4M
- Total assets
- $11.1M
- Market cap
- $42.0M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Operating expenses
- $10.5M
- Net income
- -$10.4M
- EPS (basic)
- $-1.35
- EPS (diluted)
- $-1.35
Balance sheet
- Total assets
- $11.1M
- Current assets
- $11.1M
- Total liabilities
- $702.1K
- Current liabilities
- $702.1K
- Shareholders’ equity
- $10.4M
Cash flow
- Operating cash flow
- -$4.7M
- Investing cash flow
- -$3.5M
- Financing cash flow
- $8.2M
- Net cash flow
- $0
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $42.0M
- EPS (diluted)
- $-1.35
- Shares outstanding
- 42.0M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Aug 3, 2023
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $10.4M.
- Trading 50% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review MIRA PHARMACEUTICALS, INC..
Write a review
News about MIRA PHARMACEUTICALS, INC.
News & sentiment via Polygon.io
